Trial Profile
A phase I/II trial of ganetespib in combination with paclitaxel and trastuzumab in HER2-positive breast cancer and ganetespib in combination with paclitaxel in triple negative breast cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2012
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary) ; Paclitaxel; Trastuzumab
- Indications HER2 positive breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 22 Feb 2012 Preliminary results are expected by the end of 2012, according to a Synta Pharmaceuticals media release.
- 22 Feb 2012 Planned initiation date changed from 1 Dec 2012 to 1 Mar 2012.
- 22 Feb 2012 Status changed from planning to not yet recruiting.